Find a clinical trial


If you have questions about clinical trials or want help finding the right one for you, contact our:

Patient Engagement Center Phone: 844-552-2734

This is a preliminary search of all open and enrolling clinical trials across our regions and affiliate organizations that have sponsors' permission to publish to this website.

Please use the filtering options in the right column to refine your search. Otherwise ALL open and enrolling clinical trials will display below.

Viewing Page 2 of 92 | Showing Results 6 - 10 of 459

Phase 2, Open-Label Safety and Efficacy Study of Telisotuzumab Vedotin (ABBV-399) in Subjects With Previously Treated c-Met+ Non-Small Cell Lung Cancer

This study is designed to identify the target Non-Small Cell Lung Cancer (NSCLC) population(s) that over express c-Met (c-Met+) best suited for...

Rachel Sanborn, M.D.
  • Providence Cancer Institute Franz Clinic

GO40241: A Phase III, Double-Blinded, Multicenter, Randomized Study Evaluating the Efficacy and Safety of Neoadjuvant Treatment with Atezolizumab or Placebo in Combination with Platinum-Based Chemotherapy in Patients with Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (Impower030)

The purpose of this study is to compare the effects, good or bad, of atezolizumab plus chemotherapy (in this study, chemotherapy will be a...

Timothy Byun, M.D.
  • xSJH Southern California

SJH 14-098-Alliance A151216- A Genetic Testing for patients with Resectable or resected lung cancer. Adjuvant Lung Cancer enrichment maker identification and sequencing trial (ALCHEMIST )

This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by...

Timothy Byun, M.D.
  • St. Joseph Hospital of Orange
  • xSJH Southern California

A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN)

Inclusion Criteria:•Age ≥18 years•Histologically or cytologically documented NSCLC with resectable (Stage IIA to select [ie, N2] Stage IIIB)...

Ying Zhuo, M.D.
  • Kadlec Clinic Hematology and Oncology
  • Kadlec Research
Viewing Page 2 of 92 | Showing Results 6 - 10 of 459